Orifarm Pharmaceuticals

Orifarm is a leading European pharmaceutical group that has carved out a significant niche as a specialist in both generic medicines and parallel imports. Founded in Denmark, the company's business model is built around making healthcare more affordable by sourcing original pharmaceuticals from across EU/EEA countries and repacking them for sale in other markets where prices are traditionally higher, as well as developing its own range of generic alternatives.

The group's manufacturing capabilities saw a massive expansion in 2020 following a major acquisition from Takeda Pharmaceuticals. This deal included the transfer of two substantial production sites located in Hobro, Denmark, and Łyszkowice, Poland. These facilities allow Orifarm to maintain a robust supply chain for its portfolio of over-the-counter and prescription products across the continent.

Today, Orifarm remains a privately held family business, which is a rarity in the large-scale pharmaceutical industry. This ownership structure has allowed the company to maintain a long-term strategic focus on European market expansion. The company is headquartered in Odense, Denmark, and continues to be a primary driver of pharmaceutical savings for both national health services and individual consumers throughout Europe.